Royalty Report: Drugs, Diagnostic, Disease – Collection: 211924


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Diagnostic
  • Disease
  • Therapeutic
  • Technical Know How
  • Viral Infection

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 211924

License Grant
The Licensor of the United Kingdom grants to the Canadian Licensee an exclusive, even as to Licensor, worldwide license under the Licensed Technology and a non-exclusive worldwide license under Licensed Manufacturing Know-How, in either case to make, have made, use, sell and import Bucast Products and to practice any method, process or procedure in connection with the manufacture, use, sale or importation of such Bucast Products.
License Property
The patents and Know-how are relating to the castanospermine-based alpha glucosidase inhibitor known generically as the anti-viral agent Bucast.

The Product shall mean a pharmaceutical product.

The Licensed Know-How shall mean any proprietary information owned by a third party as of the date disclosed to Licensor under Bucast License consisting of technical information, clinical information, including pre-clinical and clinical data available to Licensor regarding the Compounds or the Celgosivir Program, know-how and inventions, patentable and non-patentable, relating to the use, sale or importation of a Bucast Product, other than the Licensed Manufacturing Know-How.

Field of Use
The Field shall mean the prevention, diagnosis and treatment of viral diseases.

Celgosivir, which has been evaluated in over 500 subjects in human clinical studies to date, is a novel, oral antiviral agent under development for the treatment of chronic Hepatitis C Virus (“HCV”) infections.

IPSCIO Record ID: 203459

License Grant
Licensor grants an exclusive, even as to Licensor, license, with the right to sublicense, under Licensors interest in Collaboration Patents, and Collaboration Know-How, in each case solely to develop, make, have made, use, sell, have sold, offer for sale and import Products in the Field in the Territory; provided, however, that Licensor retains such rights under Collaboration Technology as are necessary to perform its obligations under the Research Program.

This agreement also includes Non-Exclusive Cross-Licenses where each Party hereby grants to the other Party a non-exclusive, royalty-free license, without the right to sub-license:
(i) under such Partys interest in Collaboration Know-How for the manufacture or formulation of products other than Products, including 'cocktail' and other Combination Products; and
(ii) under such Partys interest in Collaboration Know-How, solely to conduct research in the HCV Field in the Territory.

License Property
Licensor has a research program for the discovery and optimization of nucleoside inhibitors of the NS5b polymerase in hepatitis C virus.

The Collaboration Compound shall mean a Nucleoside that satisfies the chemical and technical requirements set forth, and its Related Compounds and which:
(a) is or was synthesized by or for Licensor on or before the Effective Date or during the Research Program Term; or
(b) is a Related Compound to a Collaboration Compound disclosed by Licensor to Licensee pursuant to Identification and Contribution of Collaboration Compounds and which is synthesized by or for Licensee after the Effective Date.

The Collaboration Compound Products shall mean any preparations in final form, bulk form or other form containing as an active pharmaceutical ingredient one or more Selected Compounds.

Field of Use
The Field shall mean all human and animal therapeutic, diagnostic, and prophylactic uses, including, without limitation, the treatment, prevention and prophylaxis of hepatitis C viral infections.

The HCV Field shall mean the treatment of chronic hepatitis C viral infections in humans.

The Collaboration Compound Products are for sale by prescription, over-the-counter or any other method, including without limitation any Combination Product.

IPSCIO Record ID: 203549

License Grant
For the technology, Licensor grants the Licensee of Bermuda, an exclusive, even as to Licensor, worldwide, sub-licensable license, under the Licensors Technology, to develop, make, have made, use, sell, have sold, offer for sale and import the Licensors Compounds and Products in the Primary Fields; and to develop, make and have made the Licensors Compounds and Products in the ID Field, but without any right to sell or commercialize in the ID Field. Licensee may sublicense the rights granted.

Each Party hereby grants to the other Party a non-exclusive, non-sublicensable (except to Affiliates) license to its Patent Rights and Know-How solely to the extent necessary to permit such other Party to perform its responsibilities relating to the Anadys Compound or Product under the Development Plan during the term of this Agreement.

License Property
The product is any product incorporating or comprising the Lead Compound or any other Licensors Compound in finished dosage pharmaceutical form, including, in each case, all formulations and modes of administration thereof, the development, manufacture, sale or use of such Lead Compound or other Licensor Compound would, but for the license granted hereunder, infringe the Licensor Patent Rights or incorporates or embodies Licensor Know-How.

The licensing and co-development agreement is for the development and potential commercialization of ANA975 and potentially additional Toll-Like Receptor (“TLR7”) oral prodrugs for chronic hepatitis C virus (“HCV”) and hepatitis B virus (“HBV”) infections, as well as other potential infectious disease indications.

ANA975, a 5-amino-3-ß -D-ribofuranosyl-3H-thiazolo[4,5-d]pyrimidin-2-one derivative, was synthesized in the search of an oral prodrug of isatoribine, a small molecule toll-like receptor 7 (TLR-7) agonist.

Toll-like receptor 7, also known as TLR7, is a protein that in humans is encoded by the TLR7 gene.

Field of Use
The primary field is the HCV Field and HBV Field. Primary field shall mean either the HCV Field or the HBV Field, as applicable.

ID field means the treatment, diagnosis or prevention of infectious diseases outside of the Primary Fields.

HBV field means the treatment, diagnosis or prevention of hepatitis B virus (HBV).
HCV field means the treatment, diagnosis or prevention of hepatitis C virus (HCV).

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.